found a general increase in NSE in 178 patients with breast, lung, stomach, and kidney tumours; therefore, it is believed that NSE is not specific and is elevated in almost all patients with tumours and is considered a neuroendocrine marker. The gene discussed is ENO2; the disease is neoplasm.